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Abstract
Background: The purpose of this study was to evaluate the differences in clinical characteristics and treatment
outcomes between older and younger tuberculosis (TB) patients in Korea.
Methods: We retrospectively analyzed the medical records of 271 younger (20–64 years old at diagnosis) and
199 older (≥65 years) TB patients who had been newly diagnosed and treated at Chonnam National University
Hospital from May 2008 to August 2010.
Results: Dyspnea and comorbid medical conditions were more frequent and positive TB culture rates were
higher in older TB patients. In chest computed tomography (CT) scans of pulmonary TB patients, older patients
were less likely to have micronodules (<7 mm in diameter), nodules (<30 mm in diameter), masses (>30 mm in
diameter), and cavities compared with younger patients, but were more likely to have consolidations. Incidence
of adverse drug reactions did not differ between the two groups, except for severe gastrointestinal disorders.
There were no significant differences in favorable treatment outcomes between younger and older TB patients
(97% vs. 94%, respectively; p = 0.251).
Conclusions: Older TB patients had more frequent dyspnea and less frequent active TB findings on chest CT.
Treatment success and adverse drug reaction rates were similar in older and younger TB patients.
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Background
The increase in the number of elderly people due to im-
proved life expectancy presents special challenges to the
control of tuberculosis (TB) in South Korea. In this
country, the notification rate of active TB remains as
high as 98.4 per 100,000 general population and 266.0
per 100,000 in adults aged ≥65 years [1].
It has been suggested that TB presentation in older
patients may differ from that in younger patients and
should be classified as a separate entity [2,3]. These in-
dividuals have more comorbidity, increasing the risk of
active TB and altering its presenting symptoms [4]. Al-
though several studies have described the differences
between older and younger TB patients, there were
some discordant findings on clinical presentation,
radiological findings, laboratory features, and treatment
outcomes [2-5]. Chest computed tomography (CT) is
superior to chest radiography in the diagnosis of pul-
monary TB [6-9]. However, there are no data about
differences in chest CT findings between younger and
older TB patients.
In an effort to clarify this issue, here we describe the
differences between older and younger TB patients
concerning their presenting symptoms, diagnostic find-
ings, especially focused on chest CT findings, treatment
outcomes, and adverse drug reactions.
Methods
Study population
We enrolled all adult patients aged >20 years who
were treated for newly diagnosed active TB at the
Chonnam National University Hospital between May
2008 and August 2010. We retrospectively collected
data for clinical, radiographic, and bacteriological sta-
tus of these patients. From 542 patients with newly di-
agnosed active TB, we excluded those who displayed
non-tuberculous mycobacteria in final culture results
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(n = 15), and those who had been transferred to an-
other institution after being treated for <3 months at
our hospital (n = 57). This left 470 patients with newly
diagnosed active TB who received anti-TB medication
for >3 months. Permission was obtained from the Insti-
tutional Review Board of Chonnam National University
Hospital to review and publish patient records retro-
spectively. Informed consent was waived because of the
retrospective nature of the study.
Active TB comprised two situations. The first was
definite cases that were confirmed by a positive culture
or nucleic acid amplification test for Mycobacterium
tuberculosis in clinical specimens. The second was
probable cases with caseous granuloma in tissue hist-
ology results or typical findings of active TB on radio-
logical examinations, high clinical suspicion, positive
tuberculin skin test or interferon γ release assay
(IGRA), and good clinical responses to anti-TB treat-
ment without a culture-positive result or nucleic acid
amplification test for M. tuberculosis.
Elderly patients were defined as persons aged ≥65 years
at the time of TB diagnosis. They were compared with
younger patients (20–64 years old at diagnosis). In South
Korea, a 6-month self administered regimen consisting
of a 2-month initial phase of isoniazid, rifampicin,
pyrazinamide, and ethambutol, followed by a 4-month
continuation phase of isoniazid, rifampicin, and etham-
butol has been recommended by the National Tubercu-
losis Program [10]. Alternatively, a 9-month regimen
with isoniazid, rifampin, and ethambutol can be ad-
ministered [10]. Therefore, most patients in this study
received daily therapy consisting of isoniazid (300 mg),
rifampin (450–600 mg), ethambutol (0–1200 mg), and
pyrazinamide (1500 mg). However, the decision to in-
clude pyrazinamide in the initial regimen was made by
clinicians based on each patient’s clinical situation.
Microbiological and radiological evaluations
In patients with suspected pulmonary TB, sputum acid
fast bacilli (AFBs) stain and mycobacterial cultures
were performed more than three times according to
the recommendation of the Korean TB guidelines [11].
In extrapulmonary TB, AFB stain, mycobacterial cul-
tures, and TB polymerase chain reaction (PCR) were
performed if there were available patient samples. Spu-
tum TB PCR was routinely performed on the first
sample for testing of AFB stains. We performed bron-
choscopy if patients could not expectorate sputum or
had negative AFB smear results for their sputa and
had chest images that could not differentiate from
other diseases such as a lung malignancy, fungal infec-
tions, and parasitic infestations. All specimens were
decontaminated and cultured on liquid media using
the BACTEC MGIT 960 system (Becton Dickinson,
Sparks, MD, USA). M. tuberculosis was identified by
multiplex PCR assay as described previously [12]. For all
multiplex PCRs, amplification was performed in a
GeneAmp PCR 9600 DNA thermal cycler (Perkin–Elmer,
Waltham, MA, USA). IGRA was performed using a
QuantiFERON-TB Gold In-Tube (Cellestis, Carnegie,
Vic, Australia) and the results were interpreted as speci-
fied by the manufacturer.
Chest CT scans were performed in all patients
suspected of having active pulmonary TB and could
not be differentiated from other diseases such as lung
cancer or pneumonia at the start of treatment. We
evaluated chest CT findings for evaluation of the le-
sions including [9,13]: (1) micronodule: a nodule with
a diameter <7 mm; (2) nodule: a focal, round opacity
with a diameter <3 cm; (3) mass: a round opacity with
a diameter >3 cm; (4) tree-in-bud sign: nodular dilata-
tion of centrilobular branching structures that resem-
bled a budding tree; (5) consolidation: a homogeneous
increase in lung opacity that resulted in obscuration of
underlying vessels; (6) ground glass opacity: a hazy in-
crease in lung opacity that was not associated with ob-
scuration of underlying vessels; and (7) bronchiectasis:
bronchial dilatation, often with thickening of the wall.
In addition, the presence of cavitation, fibrotic changes,
lymphadenopathy, and pleural thickening with effusion
were noted.
Treatment outcomes and adverse drug reactions
For this analysis, we applied the definitions in the World
Health Organization recommendations concerning cure,
treatment completed, treatment failure, death, default,
and transfer out [14]. For purposes of analysis, cure or
treatment completed were assigned to favorable out-
comes and death, default, and transfer out to unfavor-
able outcomes.
We evaluated adverse drug reactions that resulted in
an interruption and change of treatment with review of
medical records including: hepatotoxicity; skin rash or
itching sense; gastrointestinal (GI) problems including
nausea, vomiting, diarrhea, and dyspepsia; optic neur-
opathy; and thrombocytopenia.
Statistical analyses
Values are expressed as the mean ± standard deviation,
or as numbers (percentages) in the text and tables. The
categorical comparisons of older versus younger adults
were assessed using the χ2 test. Differences with regard
to numeric values between the older and younger pa-
tients were analyzed using the Student’s t test for vari-
ables with a normal distribution. Logistic regression
analysis was used to adjust the effects of sex difference,
the presence of underlying diseases, and smoking status
on clinical presentation between older and younger TB
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patients. A p value <0.05 was considered to be statistically
significant. Null hypotheses of no difference were rejected
for p < 0.05, or, equivalently, if the 95% confidence interval
(CI) of odds ratio (OR) estimates excluded 1. Calculations




Table 1 summarizes the baseline characteristics of the
199 older and 271 younger patients. Older TB patients
had a higher prevalence of women than the younger TB
patients had. There were more definite cases in the older
TB patients than in the younger TB patients (81% vs.
68%, p = 0.002). Among the respiratory symptoms in pa-
tients with pulmonary TB, dyspnea was more frequently
found in older TB patients compared to younger TB
patients. In the definite cases, hemoptysis was more
frequently found in younger TB patients than in older
TB patients (22% vs. 10%, p = 0.007). However after
adjusting for sex, smoking, and comorbid conditions
such as cardiovascular disease, diabetes mellitus, and
chronic obstructive pulmonary disease (COPD), there
were no differences in cough (OR, 1.49; 95% CI,
0.93–2.38), sputum (OR, 1.38; 95% CI, 0.89–2.17), dys-
pnea (OR, 1.66; 95% CI, 0.93–2.97), and hemoptysis
(OR, 0.61; 95% CI, 0.33–1.15) between the two groups.
Prevalence of comorbid conditions including cardio-
vascular diseases, diabetes mellitus, and COPD was
higher in older TB patients.
Sites of disease
Table 2 summarizes disease sites of TB in older and youn-
ger patients. There were significant differences between the
groups according to sites of infection. Pulmonary TB was
more frequent in older patients and extrapulmonary TB
was more frequent in younger patients. In cases of pul-
monary TB, there was no significant difference in lobar
predominance (upper lobe vs. middle or lower lobes)
between the age groups. However, older TB patients
displayed a higher proportion of endobronchial TB
(23/173, 13%) than did younger TB patients (12/222,
5%) (p = 0.007). In the case of extrapulmonary TB,







Gender, male 100 (51) 169 (62) 0.011
Age, median (IQR) 72 (68–76) 44 (32–55)
BMI, kg/m2 21.75 ± 3.59 21.96 ± 3.22 0.420
Ever smoking 87 (44) 129 (48) 0.454
Respiratory symptoms in
pulmonary TB*
n = 173 n = 222
Cough 118 (68) 131 (59) 0.076
Sputum 98 (57) 106 (48) 0.098
Dyspnea 39 (23) 30 (14) 0.027
Hemoptysis 20 (12) 41 (19) 0.081
Weight loss 5 (3) 23 (9) 0.785
General weakness 13 (7) 22 (8) 0.661
Fever 24 (12) 38 (14) 0.644
Night sweating 0 (0) 5 (2) 0.144
History of previous TB 31 (16) 32 (12) 0.275
Comorbid conditions**
Cardiovascular disease† 75 (38) 24 (9) <0.001
Diabetes mellitus 43 (22) 32 (12) 0.006
COPD 20 (10) 4 (2) <0.001
Chronic kidney disease 1 (1) 3 (1) 0.848
Chronic liver disease‡ 10 (5) 15 (6) 0.982
Malignancy 9 (5) 9 (3) 0.661
The data are presented mean ± standard deviation for age and pack-years of
smoking and as n (%) for all other factors.
BMI = body mass index, COPD = chronic obstructive pulmonary disease,
IQR = interquartile range, TB = tuberculosis.
*: Pulmonary tuberculosis and pulmonary and extrapulmonary tuberculosis
were included.
**: If there were more than one comorbid condition for one patient, all
comorbid conditions were recorded.
†: Hypertension and cerebrovascular disease are included.
‡: Hepatitis and liver cirrhosis are included.
Table 2 Disease sites in older and younger tuberculosis
patients
Characteristics Older Younger p-value
Sites of disease n = 199 n = 271
Pulmonary TB 155 (78) 183 (68) 0.044
Pulmonary and extrapulmonary TB 18 (9) 39 (14)
Extrapulmonary TB 26 (13) 49 (18)
Locations of pulmonary TB n = 173 n = 222
Upper* 109 (63) 159 (72) 0.066
Middle or lower 64 (37) 65 (28)
Locations of extrapulmonary TB† n = 44 n = 88
Pleural TB 24 (53) 36 (41) 0.144
Tuberculous lymphadenitis 8 (18) 31 (35) 0.046
Skeletal TB 7 (16) 10 (11) 0.582
Tuberculous pericarditis 4 (9) 2 (2) 0.095
Miliary TB 1(2) 4 (5) 0.664
Tuberculous peritonitis 2 (4) 2 (2) 0.600
CNS TB 0 (0) 1 (1) 1.000
Intestinal TB 0 (0) 3 (3) 0.550
Genitourinary TB 0 (0) 3 (3) 0.550
The data are presented as n (%).
*: Lesion of the upper lobe only or upper lobe with other lobe.
†: Including multiple locations of TB.
TB = tuberculosis.
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older patients had a lower incidence of tuberculous
lymphadenitis than younger TB patients had.
Diagnostic tests, drug resistance, and radiological
findings
The positive rate of TB culture was significantly higher
in older than in younger TB patients. Bronchoscopy was
more frequently performed in older than in younger TB
patients (Table 3). There were no significant differences
in isoniazid-resistant TB and multidrug-resistant TB be-
tween the two age groups (Table 3).
Chest CT findings of pulmonary TB revealed that
micronodules, nodules, tree-in-bud appearances, and
consolidations were the most common characteristics
in pulmonary TB. However micronodules, nodules,
masses, tree-in-bud appearance, and cavitations were
more frequently found in younger TB patients. Consol-
idations were more frequently found in older TB pa-
tients (Table 4).
Treatment outcomes and adverse drug reactions
Of all patients with pulmonary TB, favorable treatment
outcomes were achieved in 97% of older patients and
94% of younger patients, with no significant difference
(p = 0.251). Concerning unfavorable treatment outcomes
between older and younger pulmonary TB patients,
there were no significant differences in rates of mortality
(2/222 [1%] in younger TB vs. 1/172 [1%] in older TB,
p = 1.000), default (10/222 [5%] in younger TB vs. 5/172
[3%] in older TB, p = 0.443), and treatment failure (2/222
[1%] in younger TB vs. 0/172 [0%] in older TB, p = 0.507)
(Table 5).
Twenty-one percent of older TB patients and 24% of
younger TB patients experienced several adverse drug
reactions that resulted in an interruption and change of
treatment during anti-TB medication. The adverse
events included hepatotoxicity, GI problems, skin rash
or itching, optic neuropathy, and thrombocytopenia. Se-
vere GI trouble occurred more frequently in older TB
patients, whereas hepatotoxicity occurred more fre-
quently in younger TB patients (Table 5).
Discussion
In this study, 97% of older TB patients achieved favor-
able treatment outcome without increased adverse drug
reactions, with the exception of GI disorders. They were
more likely to have dyspnea and positive culture rates
for M. tuberculosis compared to younger TB patients.
Table 3 Diagnostic tests and drug resistances in older and
younger tuberculosis patients
Characteristics Older Younger p-value
Positive AFB smear 67/190 (35) 66/247 (27) 0.060
Positive culture for M.TB 155/191 (81) 169/248 (68) 0.002
Positive TB PCR 146/190 (77) 168/247 (68) 0.053
Positive IGRA 56/63 (89) 87/97 (90) 1.000
Positive tuberculin skin test 86/92 (93) 133/143 (93) 1.000
Confirmed by bronchoscopy in
pulmonary TB*
64/173 (37) 53/222 (24) 0.005
Drug resistances
Resistance to INH 10/137 (7) 15/160 (9) 0.665
Multi-drug resistance 1/137 (1) 6/160 (4) 0.185
The data are presented as n (%).
*: included both of the pulmonary tuberculosis, and pulmonary and
extrapulmonary tuberculosis.
IGRA = interferon gamma releasing assay, INH = isoniazid, MDR =multi-drug
resistant, M.TB =Mycobacterium tuberculosis, RFP = rifampin.
Table 4 Chest computed tomography findings of






Micronodules (< 7 mm) 132 (76) 191 (86) 0.018
Nodules (< 30 mm) 60 (35) 159 (72) <0.001
Masses (> 30 mm) 9 (5) 41 (18) <0.001
Tree-in-bud appearances 70 (40) 126 (57) 0.016
Consolidations 115 (66) 113 (51) 0.002
Ground glass opacities 34 (20) 30 (14) 0.130
Cavitations 27 (16) 76 (34) <0.001
Bronchiectasis 28 (16) 39 (18) 0.787
Fibrotic changes 46 (27) 77 (35) 0.100
Lymphadenopathis
(>10 mm)
42 (24) 60 (27) 0.564
The data are presented as n (%).
If there are more than one chest computed tomography findings for one
patient, all chest computed tomography findings were recorded.
Table 5 Treatment outcomes and adverse drug reactions
in older and younger tuberculosis patients
Characteristics Older Younger p-value
Treatment outcomes in pulmonary TB n = 173 n = 222
Favorable 167 (97) 208 (94)
0.251
Unfavorable 6 (3) 14 (6)
Adverse drug reactions in all patients n = 199 n = 271
Hepatotocixity* 6 (3) 13 (5) 0.338
Skin rash or itching 15 (8) 25 (9) 0.642
Gastrointestinal† problems 20 (10) 10 (4) 0.009
Optic neuropathy 2 (1) 8 (3) 0.265
Thrombocytopenia 2 (1) 2 (1) 1.0
The data are presented as n (%).
If there are more than one side effects for one patients, all side effects
were recorded.
*: Hepatotoxicity was defined when liver transaminase levels
exceeded 120 IU/L.
†:Gastrointestinal problems were problems of gastrointestinal tract for
example nausea, vomiting, diarrhea, and dyspepsia etc.
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However, active pulmonary TB indicators on chest CT,
such as nodules, masses, and cavities, were less frequently
found in older TB patients, except for consolidations.
It was previously believed that the treatment outcomes
of older TB patients were worse than those of younger
TB patients, mainly because of the high mortality rates
[15,16]. The mortality rates of older patients have been
reported at up to 51% [16,17]. Although these mortality
rates have been decreasing recently, the rate remains
high. The mortality rate in older TB patients was higher
than that in younger TB patients in the United States
from 1993 to 2008 (21% vs. 7%, p < 0.001) [16]. Also, in
a study conducted in Taiwan, the mortality rate in older
pulmonary TB was higher than that in younger patients
(27% vs. 4%, p = 0.001) [15]. In the present study, there
was no difference in mortality between younger and
older TB patients during treatment and the mortality
rate was only 0.5% (1/199) in older patients. This was
lower than the average mortality of older TB patients in
Korea (12%, 1642/14247) in 2010 [1], which could be
explained as follows. We excluded patients who received
anti-TB therapy for <3 months. However, previous stud-
ies and the epidemiological data in Korea have included
all TB patients. Therefore, patients who died early in
treatment could be excluded from the present study.
Another possible cause of the low mortality rate in older
TB patients was the high rate of bronchoscopy. Early TB
treatment can decrease TB-related mortality; therefore,
we believe that the low mortality and high treatment
success rates of older patients in our study could reflect
the ability of fiberoptic bronchoscopy to achieve a rapid
and definitive diagnosis, coupled with the opportunity to
test for drug susceptibility. We performed bronchoscopy
in 32% (64/199) of older TB patients; this rate was sig-
nificantly higher than in younger patients (20%, 53/271;
p = 0.003). However in our study, the treatment out-
comes were measured only at the end of treatment.
Therefore, long-term outcomes in TB patients might dif-
fer from these results.
Korzeniewska et al. [18] have evaluated the differences
in clinical presentations of 218 cases of pulmonary and
pleural TB between younger and older patients. Younger
patients were more likely to present with fever and night
sweats. In culture-confirmed cases, hemoptysis, fever,
and cough were more common in younger patients.
Chan et al. [19] have also evaluated the differences in
172 bacteriologically (AFB stain and/or culture) or histo-
logically confirmed TB between younger and older pa-
tients. Older TB patients had less hemoptysis but more
nonspecific symptoms than younger TB patients had. In
our study, there were no significant differences in symp-
toms, except for dyspnea, which was more frequent in
older TB patients. This difference could be a result of
more prevalent comorbid conditions in older TB
patients, because dyspnea did not differ significantly be-
tween the groups after adjusting for comorbidity. In re-
spiratory symptoms of pulmonary TB, no consistent
differences have been reported between older and youn-
ger TB patients in a meta-analysis [4], although in some
studies, TB in older patients may present atypically with
nonspecific symptoms, which can delay diagnosis
[2,3,5,20,21]. These nonspecific symptoms could be the
result of comorbid conditions in older TB patients. In a
meta-analysis, cardiovascular disorders, COPD, and dia-
betes were more prevalent in older TB patients [4]. The
higher prevalence of hemoptysis in definite cases of
younger TB patients in our study, similar to previous
studies [4,18], could have been related to the higher fre-
quency of cavities in this population.
Positive tuberculin skin test was also higher in younger
TB patients than in older TB patients in a previous study
(86% vs. 68%, p = 0.03) [18]. A decrease in immuno-
logical status associated with aging could have caused
the lower positive rate [4]. However in our study, the
positive rate in tuberculin skin test did not differ be-
tween the groups. We could not explain the exact cause
of the high positive rates in the tuberculin skin test in
older TB patients. However, it might be explained by the
high level of previous bacille Calmette–Guérin (BCG)
vaccination, which in Korea, is given at birth and again
at age 12 or 13 years if the child has a negative tubercu-
lin skin test, and presence of latent TB infection, which
is as high as 30% among Koreans [22]. However, we do
not know the exact number of BCG vaccinations and la-
tent TB infections in the present study.
The prompt diagnosis of active TB is critical for its
control program. Imaging could provide rapid diagnosis
and early treatment for active TB. However, the radio-
logical patterns of pulmonary TB in older patients have
been suggested as atypical, which may differ from those
in younger TB patients [23]. Although there was a
greater incidence of cavities in younger TB patients and
lower lung field lesions in older TB patients compared
with the other age group in previous studies, they only
compared chest radiographic findings [4,15,24]. The su-
periority of the chest CT to radiography in evaluating
many chest diseases has been established, and many
chest CT features of pulmonary TB have been described
[6-9]. To the best of our knowledge, the present study is
the first recent evaluation of the chest CT pattern in
pulmonary TB in a large group of older TB patients. In
chest CT findings of pulmonary TB, micronodules,
which are not seen on chest radiography, are known as
acute inflammatory lesions and are the most common
lesions in pulmonary TB [9]. Therefore, these lesions are
a useful diagnostic sign of active pulmonary TB. Another
important sign of active pulmonary TB on chest CT is a
tree-in-bud appearance. This represents a form of
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bronchiolar impaction in which branching linear struc-
tures have more than one contiguous branching site
[6,25]. Cavities are the most important sign of pulmon-
ary TB activity [26]. Our data show that older adults
with pulmonary TB are less likely to have typical radio-
logical patterns of active pulmonary TB such as
micronodules, tree-in-bud appearances and cavities than
younger adults with pulmonary TB have, and are more
likely to have atypical patterns such as consolidations.
These could represent detailed patterns of atypical radio-
logical presentation in older patients with pulmonary TB.
Although there was no significant difference in posi-
tive sputum smear results between older and younger
TB patients, the former had a higher proportion of posi-
tive sputum smears in our study. This is contrary to the
present radiological findings that older adults with TB
were less likely to have evidence of cavitations and more
likely to have atypical patterns on chest CT. Patel et al.
have reported the importance of flexible bronchoscopy
as a diagnostic tool in the evaluation of pulmonary TB
in elderly patients [27]. In our study, fiberoptic bron-
choscopy was more frequently performed in older TB
patients for differential diagnosis. Older TB patients
displayed a higher proportion of bacteriologically proven
cases and details of drug susceptibility than younger TB
patients did. These findings are similar to those of other
studies, in which fiberoptic bronchoscopy was reported
as an important diagnostic procedure in patients with
suspected pulmonary TB whose sputum specimens were
negative both in smear and PCR analyses [28,29].
Advanced age has been shown to raise the risk of hep-
atotoxicity during anti-TB treatment due to age-related
physiological changes and comorbid conditions that re-
quire multiple drug therapy [30-35]. However, the influ-
ence of age remains a controversial issue concerning the
risk of hepatotoxicity during anti-TB treatment because
aging has not achieved statistical significance in some
studies [36,37]. In the present study, there were no dif-
ferences in serious adverse reactions, including hepato-
toxicity, between the two groups, except for severe GI
disorders, which was higher in older TB patients. Dif-
ferent regimens such as the absence/presence of
pyrazinamide or treatment duration could cause differ-
ent rates of adverse drug reactions. However, in the
present study, there were no differences in regimens
that included pyrazinamide (97%, 264/271) in younger
TB patients versus 97% (194/199) in older TB patients
(p = 1.000), or in the duration of treatment (237 ± 102
vs. 229 ± 93 days, p = 0.373).
Conclusions
In summary, older TB patients presented more frequent
dyspnea, but on chest CT showed less frequent findings
of active pulmonary TB, such as nodules, masses, and
cavities. However, the treatment outcome and adverse
drug reactions, except for GI disorders, were no different
from those in younger TB patients.
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